Alendronate sodium and Warm type haemolytic anaemia - a phase IV clinical study of FDA data

Summary:

Warm type haemolytic anaemia is reported only by a few people who take Alendronate Sodium.

The phase IV clinical study analyzes which people take Alendronate sodium and have Warm type haemolytic anaemia. It is created by eHealthMe based on reports of 36,457 people who have side effects while taking Alendronate sodium from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 05, 2023

36,457 people reported to have side effects when taking Alendronate sodium.
Among them, 1 person (0.0%) has Warm type haemolytic anaemia.

What is Alendronate sodium?

Alendronate sodium has active ingredients of alendronate sodium. It is often used in osteoporosis. eHealthMe is studying from 37,110 Alendronate sodium users for its effectiveness, alternative drugs and more.

What is Warm type haemolytic anaemia?

Warm type haemolytic anaemia (red cell destruction due to warm antibody self defence) is found to be associated with 171 drugs and 116 conditions by eHealthMe.

Number of Alendronate sodium and Warm type haemolytic anaemia reports submitted per year:

Could Alendronate sodium cause Warm type haemolytic anaemia?

Gender of people who have Warm type haemolytic anaemia when taking Alendronate sodium *:

female: 100 %
male: 0.0 %

Age of people who have Warm type haemolytic anaemia when taking Alendronate sodium *:

Common drugs people take besides Alendronate sodium *:

Metoprolol Tartrate: 1 person, 100.00%
Coumadin: 1 person, 100.00%
Acetaminophen: 1 person, 100.00%

Common conditions people have *:

Pain: 1 person, 100.00%
High Blood Pressure: 1 person, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Alendronate sodium and have Warm type haemolytic anaemia?

Check whether Warm type haemolytic anaemia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .

Related studies

Common Alendronate sodium side effects:

Browse all side effects of Alendronate sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Warm type haemolytic anaemia treatments and more:

Warm type haemolytic anaemia (205 reports)

COVID vaccines that are related to Warm type haemolytic anaemia:

All the drugs that are associated with Warm type haemolytic anaemia:

Warm type haemolytic anaemia (171 drugs)

All the conditions that are associated with Warm type haemolytic anaemia:

Warm type haemolytic anaemia (116 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alendronate sodium (the active ingredients of Alendronate sodium) and Alendronate sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.